Vivek Jain Sells 12,000 Shares of ICU Medical, Inc. (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $17,973,261.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vivek Jain also recently made the following trade(s):

• On Tuesday, October 1st, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $178.46, for a total value of $2,141,520.00.
• On Tuesday, September 3rd, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $163.46, for a total transaction of $1,961,520.00.
• On Friday, August 16th, Vivek Jain sold 12,000 shares of ICU Medical stock. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $179.01 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. ICU Medical, Inc. has a 52-week low of $78.28 and a 52-week high of $188.53. The stock’s fifty day simple moving average is $174.46 and its 200-day simple moving average is $138.86.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. The company had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.58 EPS. On average, research analysts predict that ICU Medical, Inc. will post 3.81 EPS for the current year.

Hedge Funds Weigh In On ICU Medical

Institutional investors and hedge funds have recently modified their holdings of the company. Silvercrest Asset Management Group LLC grew its stake in ICU Medical by 109.4% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after acquiring an additional 145,485 shares during the period. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of ICU Medical during the first quarter worth $15,425,000. Victory Capital Management Inc. grew its position in shares of ICU Medical by 2,966.3% in the second quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier’s stock valued at $16,844,000 after purchasing an additional 137,222 shares during the period. Millennium Management LLC increased its stake in ICU Medical by 327.8% in the second quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock valued at $16,158,000 after purchasing an additional 104,264 shares during the last quarter. Finally, Granite Investment Partners LLC purchased a new position in ICU Medical during the second quarter worth about $10,650,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ICUI. KeyCorp increased their target price on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Jefferies Financial Group initiated coverage on ICU Medical in a research report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company. Raymond James raised their target price on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Thursday, October 10th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $170.25.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.